WO2017160106A2 - 두타스테라이드 및 탐수로신 함유 경질 캡슐 복합제 및 그 제조방법 - Google Patents

두타스테라이드 및 탐수로신 함유 경질 캡슐 복합제 및 그 제조방법 Download PDF

Info

Publication number
WO2017160106A2
WO2017160106A2 PCT/KR2017/002862 KR2017002862W WO2017160106A2 WO 2017160106 A2 WO2017160106 A2 WO 2017160106A2 KR 2017002862 W KR2017002862 W KR 2017002862W WO 2017160106 A2 WO2017160106 A2 WO 2017160106A2
Authority
WO
WIPO (PCT)
Prior art keywords
dutasteride
tamsulosin
hard capsule
self
capsule
Prior art date
Application number
PCT/KR2017/002862
Other languages
English (en)
French (fr)
Korean (ko)
Other versions
WO2017160106A3 (ko
Inventor
이벤자민준
김진철
김재호
김용일
박재현
우종수
Original Assignee
한미약품 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한미약품 주식회사 filed Critical 한미약품 주식회사
Priority to MX2018011208A priority Critical patent/MX2018011208A/es
Priority to CN201780029107.0A priority patent/CN109152743B/zh
Priority to EA201891843A priority patent/EA201891843A1/ru
Priority to AU2017233134A priority patent/AU2017233134A1/en
Priority to BR112018068686A priority patent/BR112018068686A2/pt
Publication of WO2017160106A2 publication Critical patent/WO2017160106A2/ko
Publication of WO2017160106A3 publication Critical patent/WO2017160106A3/ko
Priority to PH12018501985A priority patent/PH12018501985A1/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A61K9/5057—Gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Definitions

  • the present invention relates to a hard capsule complex containing dutasteride and tamsulosin as active ingredients. More specifically, the size of the hard capsule complex is reduced to improve drug compliance and show fast drug efficacy of dutasteride. It relates to a hard capsule complex containing a ride and tamsulosin and a method for producing the same.
  • Benign prostatic hyperplasia is a common disease in men over 50 years of age. It is a disease that causes urination disorder due to an increase in the size of the prostate gland. Benign prostatic hyperplasia can lead to complications such as urinary tract infection, urolithiasis, hematuria, and renal failure.
  • Dutasteride a 5-alpha reductase inhibitor (chemical name: 17 ⁇ -N- (2,5-bis (trifluoromethyl)) phenylcarbamoyl-4-a-5-5-androst-1-ene-3-) On) is known to be useful for treating benign prostatic hyperplasia, prostate cancer and androgenetic alopecia (Patent Document 1).
  • Dutasteride is currently marketed under the trade name AVODART, which comprises 0.5 mg of dutasteride and 349.5 mg of capryl / capric acid mono- and di-glyceride oils and butylated hydroxytoluene (A soft capsule, dissolved in a mixture of BHT) and filled into a soft capsule, is used for treating benign prostatic hyperplasia, prostate cancer and androgenetic alopecia.
  • Tamsulosin is ⁇ 1a As a blocker, it is effective not only for treating benign prostatic hyperplasia but also for treating chronic prostatitis and chronic abdominal pain syndrome. It is also effective in treating urolithiasis through muscle relaxation mechanism through ⁇ 1a blockade. Tamsulosin was developed by Yamanouchi pharmaceuticals in 1996, and various products containing tamsulosin hydrochloride are now known (Patent Document 2).
  • dutasteride and tamsulosin which are treatments for benign prostatic hypertrophy, having different mechanisms of action, are known to have an advantage in that a better therapeutic effect and side effects are reduced when they are used concurrently or at intervals of time. Therefore, a hard capsule complex containing a separate form of dutasteride and tamsulosin in a hard capsule is developed and marketed in the United States under the trade name Jalyn (GlaxoSmithKline).
  • Jalyn is an immediate release soft capsule in a HPMC hard capsule filled with dutasteride in a mixture of mono- and di-glyceride oils of capryl / capric acid and butylated hydroxytoluene (BHT) in a soft capsule. Is a form containing tamsulosin sustained-release granules (see https://www.gsksource.com/pharma/content/gsk/source/us/en/brands/jalyn.html , see section 11.description). .
  • the Jalyn is known to be effective in the treatment of prostate hyperplasia and the like due to the independent action of each component, including immediate release dutasteride and sustained-release tamsulosin existing in one complex formulation.
  • Patent Document 1 US Patent Registration 5,565,467
  • Patent Document 2 US Patent Publication 2004-0058896
  • An object of the present invention is to reduce the size of the dutasteride and tamsulosin-containing hard capsules to significantly improve the patient's medication compliance and to increase the initial dissolution rate of dutasteride and dutasteride and tamsulosin It is to provide a composite hard capsule containing.
  • Another object of the present invention is to provide a method for preparing the dutasteride and tamsulosin-containing complex hard capsule.
  • a hard capsule complex comprising a dutasteride independent portion comprising dutasteride or a pharmaceutically acceptable salt thereof and a tamsulosin independent portion comprising tamsulosin or a pharmaceutically acceptable salt thereof,
  • the dutasteride independent portion is a formulation containing a self-emulsifying emulsion comprising dutasteride, an oil and a surfactant;
  • the tamsulosin independent part is a solid preparation containing a sustained release base
  • dutasteride independent part and the tamsulosin independent part are included in a state separated from each other, and provides a hard capsule composite agent 0 to 3 capsules can be filled.
  • Preparing a self-emulsifying emulsion of dutasteride comprising admixing dutasteride or a pharmaceutically acceptable salt, oil and surfactant thereof;
  • dutasteride soft capsule comprising a self-emulsifying emulsion of dutasteride
  • dutasteride soft capsule and the tamsulosin granules or tablets inside the empty capsule to be included in one hard capsule
  • Dutasteride and tamsulosin-containing hard capsule complexes according to one aspect of the present invention can reduce the size of the hard capsules compared to conventional commercial complexes, thereby significantly improving patient compliance.
  • the dutasteride and tamsulosin-containing hard capsule complexes according to one aspect of the present invention can be expected to be faster than the conventional dissolution of the initial dissolution rate of dutasteride significantly increased.
  • FIG. 1 is a schematic diagram of a hard capsule composite according to an embodiment of the present invention.
  • FIG. 2 is a photograph of a soft capsule (bottom) including a dutasteride-containing self-emulsifying emulsion according to an embodiment of the present invention and a soft capsule (top) according to Comparative Example 1.
  • FIG. 2 is a photograph of a soft capsule (bottom) including a dutasteride-containing self-emulsifying emulsion according to an embodiment of the present invention and a soft capsule (top) according to Comparative Example 1.
  • Figure 3 is a photograph of the hard capsule composite (lower) and the hard capsule composite (top) according to Comparative Example 1 according to an embodiment of the present invention.
  • Figure 4 is a graph showing the dissolution rate test results of dutasteride of the hard capsule composite of Examples 1 to 4 and Comparative Example 1.
  • Figure 5 is a graph showing the dissolution rate test results of tamsulosin of the hard capsule composite of Examples 1 to 4 and Comparative Example 1.
  • a hard capsule complex comprising a dutasteride independent portion comprising dutasteride or a pharmaceutically acceptable salt thereof and a tamsulosin independent portion comprising tamsulosin or a pharmaceutically acceptable salt thereof,
  • the dutasteride independent portion is a formulation containing a self-emulsifying emulsion comprising dutasteride, an oil and a surfactant;
  • the tamsulosin independent part is a solid preparation containing a sustained release base
  • dutasteride independent part and the tamsulosin independent part are included in a state separated from each other, and provides a hard capsule composite agent 0 to 3 capsules can be filled.
  • dutasteride independent portion and tamsulosin independent portion means that the hard capsules are filled in separate, separate formulations so that no physical mixing of the respective active ingredients takes place.
  • the hard capsule complex may prepare the dutasteride independent portion into a soft capsule containing a self-emulsifying emulsion so that the poorly soluble pharmacologically active ingredient may be filled into a small size soft capsule, thereby reducing the size of the final hard capsule. It is expected that this will increase patient compliance with the medication.
  • the self-emulsifying emulsion refers to a composition capable of forming an emulsion by self-emulsification when mixed with water. More specifically, the self-emulsifying emulsion may include 0.1 to 1% by weight of dutasteride, 50 to 98% by weight of oil and 1 to 40% by weight of surfactant based on the total weight of the self-emulsifying emulsion.
  • the self-emulsifying emulsion comprises 0.1 to 1% by weight of dutasteride, more specifically 0.3 to 0.7% by weight, even more specifically 0.4 to 0.6% by weight based on the total weight of the self-emulsifying emulsion, 50 to oil 98 wt%, more specifically 60-96 wt%, even more specifically 65-95 wt%, 1-40 wt% surfactant, more specifically 3-40 wt%, even more specific It may include 4 to 35% by weight.
  • Dootasteride the active ingredient of the self-emulsifying emulsion
  • the oil is well mixed with the surfactant, emulsified in water to form a stable emulsion, and has sufficient solubility in the active ingredient dutasteride, and a pharmaceutically acceptable oil can be used.
  • the oil is 1 fatty acid mono-, di- or mono / di-glycerides, for example mono- or di-glycerides of capryl / capric acid (trade name: Capmul MCM), 2 Fatty acid triglycerides, more specifically intermediate fatty acid triglycerides can be used, for example fractionated coconut oil (trade name: capriol), 3 ester compounds of fatty acids and monovalent to trivalent alkanols, more specifically Ester compounds of fatty acids having 8 to 20 carbon atoms and monovalent to trivalent alkanols having 2 to 3 carbon atoms, for example isopropyl myristate, isopropyl palmitate, ethyl linoleate, ethyl oleate or propylene glycol mono
  • the oil may be 50 to 98% by weight based on the total weight of the self-emulsifying emulsion, when the content of the oil is less than 50% by weight, the active ingredient may not be sufficiently dissolved and precipitation may occur, exceeding 98% by weight. In this case, the amount of surfactant is reduced, which may lower the emulsifying ability of the preparation.
  • the solubility of dutasteride was investigated using Capmul MCM oil, and it was found that the minimum amount of oil required to dissolve 0.5 mg of dutasteride is 32 mg and the total amount of oil used must exceed 50 mg. there was. However, in consideration of miniaturization of the soft capsule, it is preferable that the amount of oil does not exceed 200 mg.
  • the content of oil may be used as about 50 mg to 200 mg.
  • the surfactant serves to stably emulsify the oil component in water to form a stable emulsion.
  • a nonionic surfactant may be used, and the nonionic surfactant may be casters such as tweens, spans, labrasol, brij, myrj, and polyoxyl caster oil.
  • Oils, substituted castor oils such as Cremophor or hydrogenated Cremophor, polyoxyethylene-polyoxypropylene block copolymers, polyoxyethylene-polyoxypropylene copolymers (trade name: Pluronic) ), Capryl / capric acid mono- or di-glycerides (trade name: Imwitor) and the like can be used.
  • the surfactant may be selected from the group consisting of substituted castor oils, polyoxyethylene-polyoxypropylene block copolymers, and any combination thereof.
  • the polyoxyethylene-polyoxypropylene block copolymers include poloxamer 407, poloxamer 188 or poloxamer 124.
  • the substituted castor oils are Cremophor ® EL which is hydrogen substituted caster oil, HG-50 (PEG50 Hydrogenated castor oil), HCO-40 (PEG40 Hydrogenated castor oil) or Polyoxyethylated castor oil. (Cremophor ® EL), Cremophor RH40 and the like.
  • the surfactant may be 1 to 40% by weight based on the total weight of the self-emulsifying emulsion, when the surfactant is less than 1% by weight, the emulsion forming ability is lowered, and when the amount exceeds 40% by weight, a desired effect is obtained compared to the amount added. It is difficult.
  • the self-emulsifying emulsion may include 0.3 to 0.7% by weight dutasteride, 60 to 96% by weight oil and 3 to 40% by weight surfactant based on the total weight of the self-emulsifying emulsion.
  • the self-emulsifying emulsion may include 0.4 to 0.6% by weight of dutasteride, 65 to 95% by weight of oil and 4 to 35% by weight of surfactant based on the total weight of the self-emulsifying emulsion.
  • the self-emulsifying emulsion may be contained 70 to 200 mg in the dutasteride independent portion, considering the minimum amount of oil required to dissolve an effective amount of dutasteride and miniaturization of the soft capsule.
  • the dutasteride independent portion is a soft capsule containing about 70-200 mg of the self-emulsifying emulsion.
  • the dutasteride independent portion, 70 to self-emulsifying emulsion comprising 0.1 to 1% by weight of dutasteride, 50 to 98% by weight oil and 1 to 40% by weight surfactant based on the total weight of the self-emulsifying emulsion It is a soft capsule containing 200 mg.
  • the dutasteride independent portion 70 to self-emulsifying emulsion comprising 0.3 to 0.7% by weight, 60 to 96% by weight of oil and 3 to 40% by weight of surfactant based on the total weight of the self-emulsifying emulsion It is a soft capsule containing 200 mg.
  • the dutasteride self-emulsifying emulsion comprises about 1: 100 to 500: 1 to 100, specifically 1: 150 to 250: 5 to 80, more specifically About 1: 150-200: 40-80.
  • the self-emulsifying emulsion of dutasteride may further comprise a phase stabilizer.
  • the phase stabilizer not only provides the solubility suitable for formulation to the active ingredient, but also helps to stabilize the phase, thereby preventing the occurrence of layer separation and precipitation and securing the uniformity of the composition even during the preservation of the formulation. .
  • the property stabilizer is water, ethanol, glycerin, propylene glycol, polyethylene glycol, diethylene glycol monoethyl ether (trade name: transcutol), dimethyl isosorbide (trade name: Arlasolve), cetyl alcohol ( cetyl alcohol) and any combination thereof, and may be, for example, water, ethanol or glycerin.
  • the property stabilizer may be included in 0.5 to 3% by weight, preferably 1 to 3% by weight based on the total weight of the self-emulsifying emulsion.
  • the self-emulsifying emulsion of dutasteride may further comprise a pharmaceutically acceptable additive, such as an antioxidant, for oral administration.
  • a pharmaceutically acceptable additive such as an antioxidant
  • the antioxidant may be selected from lipophilic tocopherols, dibutylhydroxytoluene, hydrophilic ascorbic acid, sodium sulfite, sodium pyrosulfite, and any combination thereof.
  • the dutasteride independent portion may be a soft capsule containing a self-emulsifying emulsion, and the soft capsule may be prepared as Nos. 2 to 4 soft capsules having a volume of 0.07 cc to 0.30 cc.
  • the soft capsule may also be made of a soft capsule in the form of round, oblong, or oval.
  • the soft capsule is a soft capsule in the form of 2 to 4 rounds (0.07 to 0.25 cc), 2 to 4 ovals (0.09 to 0.25 cc), or 2 to 4 O'Brien (0.08 to 0.30 cc) It may be prepared as, more specifically, 2 to 3 round (0.07 ⁇ 0.19 cc) or oval (0.09 ⁇ 0.19 cc) soft capsules, more specifically No. 2 round or 2 oval soft capsules Can be. (See Catallent, Inc., https://www.catalent.com/index.php/content/download/1230/14867/file/Catalent_Shapes_Sizes_Info.pdf ., And EP 2 575 788 A1)
  • the soft capsule may be a soft capsule of a material commonly used in the pharmaceutical field.
  • the tamsulosin standalone can be in the form of tablets, capsules, or granules.
  • the tamsulosin independent part may further comprise a pharmaceutically acceptable additive for formulation into the formulation.
  • the additives may include diluents, disintegrants, binders, stabilizers, lubricants, colorants, or any combination thereof.
  • the diluent may be selected from microcrystalline cellulose, lactose, rudipress, mannitol, calcium dihydrogen dioxide, starch, low-substituted hydroxypropyl cellulose, and any combination thereof.
  • the diluent may be used in an amount ranging from about 1 to 95 weight percent, specifically about 5 to 95 weight percent, based on the total weight of the granules, tablets, or capsules.
  • the disintegrant may be selected from crospovidone, sodium starch glyconate, croscarmellose sodium, low-substituted hydroxypropylcellulose, starch, alginic acid or its sodium salt, and any combination thereof.
  • the disintegrant may be used in an amount ranging from about 0.1 to 30% by weight, specifically about 2 to 15% by weight, based on the total weight of the granules, tablets, or capsules.
  • the binder is hydroxypropyl cellulose, hydroxypropyl methyl cellulose, polyvinyl acetic acid, polyvinylpyrrolidone, copovidone, macrogol, sodium lauryl sulfate, hard anhydrous silicic acid, synthetic aluminum silicate, calcium silicate or magnesium metasilicate aluminate Silicate derivatives such as, phosphates such as calcium hydrogen phosphate, carbonates such as calcium carbonate, and any combination thereof.
  • the binder may be used in an amount ranging from about 0.1 to 30% by weight, specifically from 2 to 20% by weight, based on the total weight of the granules, tablets, or capsules.
  • the glidants include stearic acid metal salts such as stearic acid, calcium stearate or magnesium stearate, talc, colloidal silica, sucrose fatty acid esters, hydrogenated vegetable oils, high melting point waxes, glyceryl fatty acid esters, glycerol dibehe Nate, and any combination thereof.
  • the glidants may be used in amounts ranging from 0.3 to 5% by weight, specifically from 0.5 to 3% by weight, based on the total weight of the granules, tablets, or capsules.
  • the tamsulosin independent part in particular the tamsulosin granules or tablets may be coated with a pharmaceutically acceptable coating.
  • the coating agent may be a coating agent commonly used in the art.
  • the tamsulosin independent portion may be a sustained-release or enteric granule or tablet coated with a sustained-release coating or enteric coating on the tamsulosin granules or tablets.
  • the sustained release coating agent may be selected from povidone, methyl cellulose, ethyl cellulose, triethyl citrate, hypromellose, cellulose acetate, polyvinylacetate, propylene glycol, talc, and any combination thereof, and the enteric composition.
  • the coating agent may be selected from methacrylic acid-ethyl acrylate copolymer, triacetin, cellulose acetate succinate, hypromellose phthalate, hypromellose acetate succinate, polyvinylacetate phthalate, sodium alginate, and any combination thereof. have.
  • a coating agent, each or optionally combined with the coating agent may be coated on the tamsulosin granules or tablets. With the introduction of the coating, the tamsulosin independence shows sustained or enteric release, and can be effectively used for the treatment of enlarged prostate with rapid release dutasteride.
  • the coating agent may be selected from the group consisting of povidone, propylene glycol, polyvinylacetate, ethyl methacrylate-ethyl acrylate copolymer, talc, and any combination thereof, but is not limited thereto.
  • a plasticizer may be additionally used to prevent the enteric coating layer from breaking even when stored for a long time.
  • the plasticizers include acetylated monoglycerides, triacetin, or mixtures thereof.
  • the amount of coating used is preferably kept to a minimum for providing optimal formulation size and for efficient production.
  • the coating agent may be used in an amount in the range of 0.1 to 20% by weight, specifically 2 to 10% by weight, based on the total weight of tamsulosin independent portion.
  • the hard capsule complex according to the present invention is a form including both dutasteride soft capsule and tamsulosin granules in the hard capsule, as shown in the schematic diagram of FIG.
  • the hard capsule ie, hard capsule cocapsule
  • the dutasteride independent portion and the tamsulosin independent portion in the hard capsule combination may be any cocapsule known in the art.
  • the hard capsule comprising the dutasteride independent portion and the tamsulosin independent portion may be selected from gelatin hard capsules and HPMC hard capsules.
  • the hard capsule is a gelatin hard capsule.
  • the initial dissolution rate of dutasteride can be significantly improved compared to the HPMC hard capsules, and thus there is an advantage that can be obtained fast-acting of dutasteride.
  • the immediate release of dutasteride independence further increases the intended rapid release and thus obtains the improved fastness of dutasteride, but does not affect the sustained release of tamsulosin independence, thus affecting the sustained release of tamsulosin.
  • the hard capsule is an HPMC hard capsule.
  • the HPMC hard capsules may be advantageous in terms of storage stability and dissolution rate of the active ingredient compared to gelatin hard capsules in a high temperature and high humidity storage environment. This is because gelatin capsules are aging due to entanglement with internal soft dutasteride capsules under high temperature and high humidity conditions, thereby reducing the dissolution rate of dutasteride.
  • HPMC hard capsule refers to a hard capsule manufactured using hydroxypropyl methylcellulose as a periodic agent.
  • gelatin hard capsule refers to a hard capsule prepared using gelatin as a periodic agent.
  • the hard capsule complex of the present invention more specifically, the dissolution rate of the dutasteride in the dissolution test according to the paddle method of the USP dissolution test item is more than about 85% in 15 minutes, more specifically Is more than about 90% hard capsule combination.
  • the hard capsule complex of the present invention is a hard capsule complex having a dissolution rate of dutasteride of about 80% or more in 30 minutes in the dissolution test according to the paddle method of the USP dissolution test item.
  • the hard capsule combination may be administered orally.
  • the empty capsule for filling the dutasteride independent portion and tamsulosin independent portion for the preparation of the hard capsule complex is possible without limitation as long as the general capsule size used in medicine.
  • the hard capsule complex may reduce the volume of the dutasteride independent portion by introducing a soft capsule containing the self-emulsifying emulsion, so that the hard capsules of 0 to 3 hard capsules (hard capsules having an internal filling amount of about 0.27 cc to 0.68 cc) ) Can be filled with both pharmaceutically effective amounts of dutasteride independent and tamsulosin independent.
  • the capsules have various internal capacities depending on the number of capsules.
  • the number 00 capsule is about 0.95 cc
  • the number 0 capsule is about 0.68 cc
  • the number 1 capsule is about 0.47 cc
  • the number 2 capsule is about 0.37 cc
  • the number 3 capsule is About 0.27 cc
  • 4 capsules have an internal dose of about 0.20 cc. (See Seoheung, http://www.suheung.com/korea/embocaps31.html )
  • the hard capsule combination can be significantly reduced in size compared to conventional commercial formulations (see Examples 1 and 2), which can significantly increase the ease of taking the patient during oral administration.
  • the blank capsule of the hard capsule combination may be 0, 1, 2, or 3 hard capsules.
  • the hard capsule complex has a rapid effect on the treatment of benign prostatic hyperplasia, prostate cancer and androgenetic alopecia by containing dutasteride, a 5-alpha reductase inhibitor, as the first active ingredient, ⁇ 1a
  • a blocking agent as a second active ingredient, it can have a continuous effect on the treatment of urination disorders such as benign prostatic hyperplasia, chronic prostatitis, chronic abdominal pain syndrome symptoms, urolithiasis, and the like.
  • the hard capsule combination may be used for the treatment of benign prostatic hyperplasia.
  • the hard capsule complex may include any amount known to be contained in the preparation of dutasteride and tamsulosin per unit dosage form, for example, about 0.2 of dutasteride per unit dosage form as free base. ⁇ 1 mg, may comprise about 0.1 to 0.8 mg of tamsulosin as free base. In one embodiment, the hard capsule complex contains about 0.5 mg of dutasteride free base as an active ingredient of the dutasteride independent portion, and about 0.4 mg of tamsulosin hydrochloride as the active ingredient of the tamsulosin independent portion.
  • dutasteride independent portion comprising dutasteride or a pharmaceutically acceptable salt thereof
  • tamsulosin independent portion comprising tamsulosin or a pharmaceutically acceptable salt thereof
  • the dutasteride independent portion contains dutasteride or a pharmaceutically acceptable salt thereof in an amount of about 0.5 mg in terms of dutasteride free base, and is eluted according to the paddle method of the USP dissolution test item.
  • the dissolution rate of dutasteride is about 80% by weight or more in 30 minutes, more specifically, the dissolution rate of dutasteride exceeds about 85% by weight in 15 minutes,
  • the tamsulosin independent part contains 0.2 mg or 0.4 mg of tamsulosin or a pharmaceutically acceptable salt thereof per unit dosage in terms of tamsulosin free base, and according to the paddle method of the USP dissolution test item.
  • the dissolution rate of the tamsulosin is about 34 wt% or less in 2 hours, about 47 to 68 wt% in 3 hours, and about 80 wt% or more in 8 hours.
  • the fixed-dose complexing agent includes the dutasteride independent portion and the tamsulosin independent portion separated from each other, and provides capsule composites filled with 0 to 3 capsules.
  • the fixed dose combination agent is a formulation containing a self-emulsifying emulsion comprising dutasteride, an oil and a surfactant;
  • the tamsulosin independent part may include a solid preparation containing a sustained release base.
  • Preparing a self-emulsifying emulsion of dutasteride comprising admixing dutasteride or a pharmaceutically acceptable salt, oil and surfactant thereof;
  • dutasteride soft capsule comprising a self-emulsifying emulsion of dutasteride
  • dutasteride soft capsule and the tamsulosin granules or tablets inside the empty capsule to be included in one hard capsule
  • the self-emulsifying emulsion of dutasteride may be prepared in the form of a liquid by homogeneously dissolving dutasteride, oil and surfactant by mixing and stirring, and if necessary, add a phase stabilizer and / or an antioxidant to It may further comprise adding and mixing and stirring.
  • Dutasteride soft capsules comprising the self-emulsifying emulsion of dutasteride may be prepared by filling the soft capsule with the self-emulsifying emulsion of dutasteride according to a conventional pharmaceutical preparation process.
  • the step of preparing tamsulosin granules or tablets may be prepared according to a conventional method for producing granules or tablets. If necessary for the manufacture of the granules or tablets, the granules or tablets may further comprise the step of coating according to a conventional coating method using the coating, for example, a sustained release coating or enteric coating.
  • Dutasteride independent portion and tamsulosin independent portion were prepared according to the following prescription.
  • the dutasteride independent part dissolved the dutasteride in mono and diglyceride oil, and then added and dissolved all the remaining components to prepare a self-emulsifying emulsion.
  • the self-emulsifying emulsion was prepared in a soft capsule to prepare a dutasteride soft capsule.
  • the prepared self-emulsifying emulsion was filled with a ribbon thickness of 0.65 mm in two rounds or a ribbon thickness of 0.75 mm in two ovals using a rotary automatic charger. Then, it was molded and dried to prepare a dutasteride soft capsule.
  • a photograph of the prepared capsule is shown in FIG. 2 (bottom).
  • the tamsulosin independent unit mixed all of the above-mentioned tamsulosin hydrochloride, microcrystalline cellulose, and hypromellose in powder form, and then granulated the solution by dissolving 18 mg of polyvinyl acetic acid in one capsule as a binding solution.
  • the tamsulosin independent unit mixed all of the above-mentioned tamsulosin hydrochloride, microcrystalline cellulose, and hypromellose in powder form, and then granulated the solution by dissolving 18 mg of polyvinyl acetic acid in one capsule as a binding solution.
  • the tamsulosin granules prepared above were coated with a solution of povidone, propylene glycol, and 2 mg of polyvinyl acetic acid in one capsule in water as an endothelial coating solution, and then the methacrylic acid-ethyl acrylate copolymer and tria
  • the coat was further coated with a coating solution dissolved in cetine to prepare tamsulosin hydrochloride granules, and then sucrose stearate was added and mixed.
  • the prepared dutasteride soft capsule and tamsulosin granules were filled in gelatin hard capsule No. 1 (Seoheung Co., Ltd.) to prepare a gelatine hard capsule complex containing 0.5 mg of dutasteride and 0.4 mg of tamsulosin hydrochloride.
  • a photograph of the prepared capsule is shown in FIG. 3 (bottom).
  • crospovidone was added as a disintegrating agent, mixed, tableted using a circular punch having a diameter of 6.5 mm, and combined with dutasteride soft capsule. It was filled into gelatin hard capsule No. 0 (Seoheung Co., Ltd.) to prepare a capsule composite.
  • the dutasteride independent part was prepared in the same manner as in Example 1, and the tamsulosin independent part was prepared as in the following prescription.
  • the tamsulosin independent unit mixed all of the above-mentioned tamsulosin hydrochloride, microcrystalline cellulose, hypromellose, and talc 6.0 mg in powder form, and then combined the solution of 12.0 mg of methacrylic acid-acrylic acid copolymer in water.
  • Granules were prepared.
  • the tamsulosin hydrochloride granules were prepared by coating the tamsulosin hydrochloride granules using 7.0 mg of methacrylic acid-acrylic acid copolymer, triacetin, and 3.0 mg of talc in water as an enteric coating solution. Stearate was added and mixed to prepare tamsulosin granules.
  • the tamstatosin granules and the dutasteride soft capsules prepared in Example 1 were filled in gelatin hard capsule No. 1 (Seohheung), and a gelatin hard capsule complex comprising 0.5 mg of dutasteride and 0.4 mg of tamsulosin hydrochloride Was prepared.
  • HPMC hard capsule No. 1 Qualicap®
  • gelatin hard capsule No. 1 in Example 1, in the same manner as in Example 1, 0.5 mg of dutasteride and 0.4 of tamsulosin hydrochloride 0.4 HPMC hard capsule complex containing mg was prepared.
  • the dissolution test was performed using 900 mL of 0.1 N hydrochloric acid solution containing 1% (w / v) cetyltrimethylammonium bromide (CTAB) according to the Paddle method in the USP dissolution test section. Elution test solution samples were taken at 5 minutes, 10 minutes, 15 minutes, 30 minutes, 45 minutes, and 60 minutes after the initial stage and the start of the test, and liquid chromatography was performed under the following conditions to calculate dutasteride dissolution rate.
  • CTL cetyltrimethylammonium bromide
  • Dissolution medium 0.1N hydrochloric acid solution containing 1% (w / v) cetyltrimethylammonium bromide (CTAB)
  • the solution was placed in a sinker and eluted for 120 minutes using 750 mL of acidic solution at 50 rpm, followed by 250 mL of buffer test solution. . Samples were taken with 10 mL of the dissolution test solution at 120 minutes, 180 minutes, 240 minutes, 360 minutes and 480 minutes after the initial and test start. The collected sample was subjected to liquid chromatography under the following conditions and the tamsulosin dissolution rate was calculated.
  • Mobile phase 8.7 mL of perchloric acid and 3.0 g of sodium hydroxide were dissolved in 1900 mL of water, adjusted to pH 2.0 with sodium hydroxide, and added to water to 2000 mL. 480 mL of acetonitrile was added to 1520 mL of this solution to obtain a mobile phase.
  • the gelatin capsule complexes according to Examples 1, 2, 3, the initial dissolution rate of dutasteride 30 minutes before the HPMC capsule complexes according to Comparative Examples 1 and 4 markedly It was found that the difference between the tamsulosin formulations of Examples 1, 2, and 3 did not significantly affect the dissolution of dutasteride. Therefore, the gelatin hard capsule complex according to one embodiment of the present invention is expected to be fast-acting dutasteride.
  • Example 3 and Comparative Example 1 since the prescription is different, the acid resistance is strong, but the gelatin capsule composite according to Examples 1 and 2, and the HPMC capsule composite according to Example 4 The dissolution results were all similar. Therefore, it was confirmed that changing the cocapsule of the hard capsule did not affect the sustained release form of the independent tamsulosin.
  • the immediate release of the dutasteride independent portion is improved in the intended immediate release, while the fast release of the dutaslide, while in the sustained-release tamsulosin independent portion As it did not affect the effect of tamsulosin was confirmed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PCT/KR2017/002862 2016-03-16 2017-03-16 두타스테라이드 및 탐수로신 함유 경질 캡슐 복합제 및 그 제조방법 WO2017160106A2 (ko)

Priority Applications (6)

Application Number Priority Date Filing Date Title
MX2018011208A MX2018011208A (es) 2016-03-16 2017-03-16 Complejo de capsula dura que contiene dutasterida y tamsulosina y metodo de preparacion del mismo.
CN201780029107.0A CN109152743B (zh) 2016-03-16 2017-03-16 含有度他雄胺和坦索罗辛的硬胶囊复合物及其制备方法
EA201891843A EA201891843A1 (ru) 2016-03-16 2017-03-16 Дутастерид- и тамсулозинсодержащий комплекс в виде твердой капсулы и способ его получения
AU2017233134A AU2017233134A1 (en) 2016-03-16 2017-03-16 Dutasteride- and tamsulosin-containing hard capsule complex and preparation method therefor
BR112018068686A BR112018068686A2 (pt) 2016-03-16 2017-03-16 formulação de compósito de cápsula dura, formulação de compósito de dose fixa e método de preparação da formulação de compósito de cápsula dura
PH12018501985A PH12018501985A1 (en) 2016-03-16 2018-09-14 Dutasteride-and tamsulosin-containing hard capsule complex and preparation method therefor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2016-0031468 2016-03-16
KR20160031468 2016-03-16

Publications (2)

Publication Number Publication Date
WO2017160106A2 true WO2017160106A2 (ko) 2017-09-21
WO2017160106A3 WO2017160106A3 (ko) 2018-09-07

Family

ID=59850978

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/002862 WO2017160106A2 (ko) 2016-03-16 2017-03-16 두타스테라이드 및 탐수로신 함유 경질 캡슐 복합제 및 그 제조방법

Country Status (8)

Country Link
KR (1) KR101968754B1 (ru)
CN (1) CN109152743B (ru)
AU (1) AU2017233134A1 (ru)
BR (1) BR112018068686A2 (ru)
EA (1) EA201891843A1 (ru)
MX (1) MX2018011208A (ru)
PH (1) PH12018501985A1 (ru)
WO (1) WO2017160106A2 (ru)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW369521B (en) 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
UA80393C2 (ru) 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтическая композиция, которая содержит ингибитор фдэ 4, диспергированный в матрице
EP1618873B1 (de) * 2004-07-14 2007-06-06 Siegfried Generics International AG Granulat zur kontrollierten Freisetzung von Tamsulosin, enthaltend Alginat
WO2006055659A2 (en) * 2004-11-15 2006-05-26 Smithkline Beecham Corporation Fixed dose combination op dutasteride and tamsulosin
CN102247379A (zh) * 2011-01-12 2011-11-23 北京润德康医药技术有限公司 一种复方制剂及其制备方法
CN102145007B (zh) * 2011-03-03 2013-03-20 王致中 一种非那雄胺软胶囊与盐酸坦索罗辛胶囊复方制剂、所用胶囊及制备方法
WO2014002015A1 (en) * 2012-06-25 2014-01-03 Ranbaxy Laboratories Limited Pharmaceutical composition comprising dutasteride
WO2014147096A1 (en) * 2013-03-19 2014-09-25 Galenicum Health S.L. Pharmaceutical compositions comprising an active agent
CN105073100A (zh) * 2013-06-21 2015-11-18 沃克哈特有限公司 坦索罗辛或其盐的药物组合物
ES2555485T1 (es) * 2014-05-26 2016-01-04 Galenicum Health S.L. Composiciones farmacéuticas que contienen un agente activo
KR101590072B1 (ko) * 2014-12-23 2016-01-29 한미약품 주식회사 두타스테라이드를 포함하는 자가유화 약물전달 시스템용 조성물

Also Published As

Publication number Publication date
MX2018011208A (es) 2019-05-30
WO2017160106A3 (ko) 2018-09-07
BR112018068686A2 (pt) 2019-01-15
PH12018501985A1 (en) 2019-07-08
CN109152743B (zh) 2022-01-07
CN109152743A (zh) 2019-01-04
KR101968754B1 (ko) 2019-04-12
EA201891843A1 (ru) 2019-04-30
KR20170107933A (ko) 2017-09-26
AU2017233134A1 (en) 2018-10-04

Similar Documents

Publication Publication Date Title
WO2018070671A1 (ko) 레날리도마이드의 경구용 정제 조성물
WO2020040438A1 (ko) 에스오메프라졸 및 탄산수소나트륨을 포함하는 우수한 방출특성을 갖는 약제학적 제제
EP3089739A1 (en) Composite formulation for oral administration comprising ezetimibe and rosuvastatin
WO2018030862A1 (ko) 탐수로신 염산염 함유 서방성 펠렛을 포함하는 용출률이 제어된 경구투여용 약제학적 제제
WO2011152652A2 (ko) 1일 1회 투여로 최적의 약리학적 임상 효과를 제공하는 아세클로페낙 서방성 제제
WO2020022708A1 (ko) 비알콜성 지방간염의 예방 또는 치료용 약학 조성물
WO2018097629A1 (ko) 바레니클린 서방성 제제 및 이의 제조 방법
WO2018080104A1 (ko) 에스오메프라졸 함유 복합 캡슐제 및 그 제조방법
WO2018062964A1 (ko) 용출율이 향상된 라록시펜, 및 비타민 d 또는 그 유도체를 포함하는 복합 캡슐제 및 이의 제조방법
WO2016013795A1 (ko) 서방성 제제
WO2020242132A1 (ko) 디메틸푸마르산염을 함유한 장용성 정제
WO2017160106A2 (ko) 두타스테라이드 및 탐수로신 함유 경질 캡슐 복합제 및 그 제조방법
WO2023068839A1 (ko) 몬테루카스트 또는 이의 약학적으로 허용가능한 염 및 레보세티리진 또는 이의 약학적으로 허용가능한 염을 함유하는 안정성이 개선된 필름코팅 정제
WO2019221488A1 (en) Pharmaceutical formulation comprising apixaban and method for preparing the same
WO2013157840A1 (ko) 안정성이 향상된 암로디핀 및 로잘탄을 함유하는 복합제 조성물
WO2021125824A1 (ko) 시벤졸린 또는 이의 염을 포함하는 약학 제형
WO2017155350A1 (ko) (±)-2-[2-(3-카르복시프로피오닐옥시)-3-디메틸아미노프로폭시]-3'-메톡시비벤질 또는 그의 염을 포함하는 경구용 약학 조성물
WO2016024844A1 (ko) 오메가-3 지방산 에스테르 및 스타틴계 약물을 포함하는 경구용 복합제제
WO2016195153A1 (ko) 약제학적 복합제제
WO2021167364A1 (en) Pharmaceutical composition comprising esomeprazole and sodium bicarbonate having excellent release properties
WO2015102337A1 (ko) 클로미프라민 함유 약학 조성물 및 이의 제조 방법
WO2013169082A1 (ko) 보센탄 제어방출성 경구제제
WO2021020771A1 (ko) 에스오메프라졸 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물
US20190030006A1 (en) Surfactant-free hiv protease inhibitor composition and method of manufacturing thereof
WO2019245150A1 (ko) 실로스타졸과 스타틴계약물을 함유하는 약학 조성물

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201891843

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2018/011208

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2017233134

Country of ref document: AU

Date of ref document: 20170316

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112018068686

Country of ref document: BR

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17767007

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 112018068686

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20180914

122 Ep: pct application non-entry in european phase

Ref document number: 17767007

Country of ref document: EP

Kind code of ref document: A2